# Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology

> **NCT05969938** · — · UNKNOWN · sponsor: **WeiWei Xiao** · enrollment: 50 (estimated)

## Conditions studied

- Rectal Adenocarcinoma
- Circulating Tumor DNA
- Minimal Residual Disease
- Neoadjuvant Chemoradiotherapy

## Interventions

- **DIAGNOSTIC_TEST:** MRD detection

## Key facts

- **NCT ID:** NCT05969938
- **Lead sponsor:** WeiWei Xiao
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-21
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-08-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05969938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05969938, "Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT05969938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*